Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1010 vs Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years
NCT06602024Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Sep 2024
- Primary completion
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 11
01
Overview
A Phase 3 trial of mRNA-1010 in seasonal influenza, sponsored by Moderna Inc. Started Sep 2024; status: completed.
02
Drugs
mRNA-1010
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT06602024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06602024.